India’s Pharmaceutical Quality Issues Could Soon Extend to Generic Versions of Ozempic

Last year, Americans spent more than $15 billion on Novo Nordisk’s diabetes and weight-loss drugs Ozempic and Wegovy. The active ingredient in both treatments — semaglutide— has rapidly become one of the world’s most commercially successful medicines.

In 2024, global sales of semaglutide-based treatments reached $26 billion, making it the second-highest-grossing prescription drug worldwide. Demand continues to expand at an extraordinary pace, with annual growth approaching 40 percent.

Patent protections for semaglutide remain in place in the United States and several other markets until the early 2030s. However, exclusivity will begin to expire in certain countries as early as 2026, including major pharmaceutical manufacturing hubs such as India and China.

India’s pharmaceutical industry is preparing to supply lower-cost versions of semaglutide as those patents lapse outside the United States. Prices in some markets could reportedly fall to as little as $40 per month, and Indian manufacturers are positioning themselves to serve dozens of countries.

These developments could significantly reshape global supply chains and pricing dynamics. They also raise important questions about quality, safety and manufacturing integrity, areas where India’s pharmaceutical industry has faced persistent scrutiny.

Over the past decade, the Food and Drug Administration has repeatedly cited Indian pharmaceutical facilities for serious safety failures, including data integrity violations, sanitation deficiencies, and manufacturing practices that would not meet U.S. standards. In 2025, the FDA issued warning letters to six Indian drug manufacturers for repeated contamination-related issues.

Many of these enforcement actions involved conventional small-molecule oral tablets and capsules. That’s notable because these products are generally far less complex to manufacture than injectable biologics. Research has shown that generic drugs produced in India are 54 percent more likely to be associated with serious adverse events compared to those manufactured in the United States or Europe. In at least one case, FDA findings tied production failures at an Indian facility to multiple U.S. patient deaths.

These incidents are not isolated. FDA warning letters, import alerts and plant shutdowns have become recurring features of the U.S.-India pharmaceutical trade. Warning letters to Indian drug manufacturers more than doubled between 2023 and 2024.

Semaglutide, however, is not a conventional small-molecule drug. It is a peptide-based injectable biologic requiring ultra-sterile production environments, precise temperature and stability controls, validated cold-chain logistics, accurate dosing, device integration, and stringent real-time data integrity systems. The margin for error is narrow, and the consequences of failure are serious.

There is still time before generic semaglutide reaches the U.S. market. Patent protections in the U.S. extend into the 2030s. However, what unfolds abroad in the coming years will help to determine the global manufacturing baseline.

Once production capacity, supply chains and pricing expectations are established overseas, the U.S. market will face a vacuum when exclusivity ends. It will enter a competitive landscape already shaped by foreign manufacturing systems.

The question for U.S. policymakers is not whether lower-cost semaglutide will eventually be available. It is whether, when U.S. patent protection expires, America will have strong domestic manufacturing capacity for complex biologics — or whether it will be heavily dependent on offshore supply chains that continue to struggle with safety, quality and compliance for less complicated drugs.

If quality concerns already affect small-molecule generics, the risks could be magnified when dealing with complex injectable biologics.

The semaglutide expansion now underway is more than a pricing story. It is an early indicator of how the next generation of biologic medicines may be produced and distributed globally. Policymakers can shape that future now — or inherit its consequences later.